CJC-1295 with ipamorelin and GHRP-2 dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
CJC-1295 with ipamorelin and GHRP-2 is three growth hormone boosters in one vial, often 2 mg each in a 6 mg vial.
Evidence grade for CJC-1295 with ipamorelin and GHRP-2: Moderate. The rule: at least one finished study in people, and at least 100 people who took it. The sum on this page: 2 completed trials, 117 people given it. A grade counts how much has been done to people, not whether it works.
- People given it
- 117
- Human studies
- 2
- Found nothing
- 0
Dose
No human dose established
Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose.
2 completed trials, 117 people given it
5 effects reported, 4 unwanted, 1 wanted, by people using it, not a trial
Goal pages: Fat loss and metabolism, Hormones and growth hormone, Gut health
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
Three growth hormone peptides in one vial, usually 2 mg of each. Three sounds better than two. Here is the thing. Two of the three hit the exact same switch. So you are getting two switches, one of them pressed twice. Nobody has tested this mix.
What people take it for
- Better sleep.
- Losing fat and holding muscle.
- Healing faster.
- People who think more ingredients means more effect.
What studies in people showed
No study has tested three of these together. No study has even tested two peptides at the same switch together. The real combination work paired one GHRP with GHRH by drip, and that beat GHRH alone in healthy older adults. One GHRP was enough to show it. Here is why the third ingredient is a step backwards. Ipamorelin got picked in the first place because it stirs up less cortisol, less prolactin and less hunger than the older ones. GHRP-2 is one of the older ones. A study with a dummy group showed it raises food intake in healthy men. Putting it back in undoes the reason you chose ipamorelin. The math: mix 6 mg with 2 mL and every unit mark carries 10 micrograms of each. Draw 10 units and you took 100 micrograms of each. That is 200 micrograms hitting the hunger switch, and the label never shows it that way.
What people report
Reports, not study results
The good
- Deep sleep and vivid dreams early on.
The bad
- Strong hunger, which surprises people who picked ipamorelin to avoid it.
- Water retention, puffy hands and carpal tunnel type symptoms, reported more here than on two part blends.
- Flushing after the shot.
- No schedule fits. If the vial holds the long acting GHRH molecule, its half life is 5.8 to 8.1 days while the other two are gone in hours. Daily piles one up. Weekly wastes two.
Where these come from: Peptide and gym forums, seller listings and clinic write-ups. People talking. The hunger effect is backed by a proper human study of one of the ingredients.
My bottom line
Three names on a label, two mechanisms, one of them doubled. You are paying extra to bring back the side effect the newer peptide exists to avoid.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
Measured in people
Goals CJC-1295 with ipamorelin and GHRP-2 has been tested for in people, biggest studies first. We count only what the studies on this page say, so the real numbers may be higher.
- Gut and digestion117 people · 1 study
- Growth hormone and IGF-1no headcount stated · 2 studies
- Feeling less hungryno headcount stated · 1 study
What people using it report
Real people telling you what happened to them. Nobody checked it, and the people who post are not a fair sample, so it cannot prove anything works. It is still the best guide on this page to what people actually do with CJC-1295 with ipamorelin and GHRP-2, what they expect, and what goes wrong. The full account, including the negative reports, is below.
33 of the 36 indexed goals have no study of any kind behind CJC-1295 with ipamorelin and GHRP-2
No study in people, animals or cells on this page reports a result for these. That does not prove CJC-1295 with ipamorelin and GHRP-2 does nothing for them. It does mean anything you have heard about CJC-1295 with ipamorelin and GHRP-2 and one of these did not come from a study cited here.
Show full evidence
What is CJC-1295 with ipamorelin and GHRP-2?
CJC-1295 with ipamorelin and GHRP-2 is three growth hormone boosters in one vial, often 2 mg each in a 6 mg vial. Two of the three press exactly the same switch. That is the fact this product hides. Nobody has studied the mix. Adding a second hunger-hormone type peptide to the first brings the older one's hunger and stress hormone effects. It does not add a second way of working.
Three is the number that should make a buyer stop. Ipamorelin and GHRP-2 both press the same switch, the hunger hormone switch. They are not two ways of working. They are two drugs on one target. Putting both in a vial is closer to taking a bigger dose of one than to mixing two different approaches.
That matters because of why ipamorelin exists at all. It was picked from this family because it releases growth hormone with less effect on the stress hormone cortisol and the hormone prolactin than the older peptides. GHRP-2 is one of the older peptides. Say a buyer chose ipamorelin to avoid the hunger, cortisol and prolactin of the older ones. Then they bought a vial with both. They have undone their own choice.
The third ingredient is the only one that works a different way. A GHRH copy makes each burst of growth hormone bigger, through a different switch. There is real evidence for pairing a GHRH drug with one hunger-hormone type drug. A 24 hour drip of GHRP-2 with GHRH raised growth hormone more than either alone in healthy older adults. One GHRP would have done that.
The math on the common 2 plus 2 plus 2 vial. Six milligrams of powder mixed with 2 mL of water gives 3 mg per mL in all, and 1 mg per mL of each. So one mark on a 100 unit insulin syringe holds 10 micrograms of each. A 10 unit draw is 100 micrograms of each. Now look at the hunger switch side. At 10 units you have taken 200 micrograms of hunger-switch peptide in total. That is twice what someone using one alone would call 100 micrograms. The label never shows it that way.
Some versions of this vial use CJC-1295 with DAC. Half of that is gone only after 5.8 to 8.1 days. It sits next to two peptides that are gone in hours. That is not a timing problem you can fix. Dose daily and the long one builds up for weeks. Dose weekly and the two short ones are missing six days out of seven.
How does CJC-1295 with ipamorelin and GHRP-2 work?
Two of the three press the same hunger hormone switch. At that switch they stack like a bigger dose. They do not help each other in different ways. The third presses the GHRH switch and makes each growth hormone burst bigger. All three end at growth hormone release from the pituitary gland, and then at IGF-1 made by the liver. So blood tests cannot tell you which of the three did anything.
What have studies in people found about CJC-1295 with ipamorelin and GHRP-2?
No study of the three together. No study of any two hunger-hormone type peptides given together.
- Ipamorelin: one proper study, 117 surgery patients. People on the dummy drip did just as well on what it measured.
- Pairing a GHRH drug with one GHRP: in healthy older adults, by drip, the pair raised growth hormone more than either alone.
- GHRP-2: makes healthy men eat more, and kept growth hormone raised over 30 days of nonstop drip.
- Two hunger-hormone type peptides together: never studied in people. There is no reason to expect more than a bigger dose of one.
- The blend: no published study and no listed trial.
What this does not tell you: Every result here is a hormone level in the blood. Nothing in this research measures the body shape, recovery or ageing results the product is sold for.
What do people who took CJC-1295 with ipamorelin and GHRP-2 report?
This is what real people say happened to them, good and bad. Nobody measured it. A report cannot tell a real effect from the lift people get just from expecting it to work, from a diet or training change made at the same time, or from what was really in the vial. We still put it near the top. It is the next best thing to a study in people: what happens when real people use it, including what goes wrong.
- Strong hunger. People put this down to the GHRP-2, and it often surprises those who chose ipamorelin to avoid it.
- Deep sleep and vivid dreams early on.
- Water retention, puffy hands and wrist nerve symptoms like carpal tunnel at higher draws. This comes up more than with two-ingredient blends.
- Flushing after the shot.
- Confusion about dosing, because the three have no shared timing.
Sources: Peptide and bodybuilding forums, vendor listings and clinic write-ups. Uncontrolled self-reports. The appetite effect has controlled human support for GHRP-2 specifically.
The state of the research
This vial shows how the number of ingredients gets used as a stand-in for how well it works. Three ingredients look like more than two on a label. In the body it is two ways of working, and one of them is given twice. The second dose brings back the hunger and stress hormone effects the newer peptide was chosen to avoid.
The spread in how long each one lasts is the second problem with no fix. One ingredient is built to last for days. Two are gone in hours. A daily plan that suits the short ones builds up the long one. A weekly plan that suits the long one leaves the short ones missing most of the week. There is no right timing for this vial. There is only a choice about which ingredient to dose wrong.
The evidence, in charts
Fig. 1a · how many people
117people, across 1 study in people cited here
| Study | People | Share |
|---|---|---|
| International Journal of Colorectal Disease 2014 | 117 | 100% |
The whole total is one study of 117. Counts are the number of people each study on this page says it signed up. That includes studies that only watched people and gave nobody the compound. 3 more studies in people give no headcount and are not counted here. Studies still signing people up are left out, and only studies cited on this page are counted.
Fig. 1b · evidence mix
All 4 sources here are studies in people.
- Study in people · done in people4100%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
The studies cover 4 different years, 2004 to 2014, counted from the list of sources on this page. The newest source on file is from 2014, more than five years ago. Research on it may have gone quiet.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four countries shown. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 4 · how much does what
Nobody has tested different amounts in people
This chart would show how the effect changes as the amount goes up. For this compound, nobody has measured that in people. So we leave it empty. We will not borrow an animal chart and pretend it works the same in people.
Fig. 5 · what the molecule is
- Kind of compound
- Blend
- Molecule weight
- Not on file
- Half-life
- Stated in words, not a numbersee the exact wording below
- Chain length
- None on file
Half-life as stated on file: Not defined for the blend, and the mismatch is the point. Two components are gone quickly while the third can persist, and the mixture has never been measured.
No amino acid sequence is on file for CJC-1295 with ipamorelin and GHRP-2, which is expected: a blend is not built from amino acids.
Fig. 6 · what is in the vial
33.3%of a 6 mg CJC-1295 with ipamorelin and GHRP-2 vial is CJC-1295 (with DAC)
- CJC-1295 (with DAC)2 mg33.3%
- Ipamorelin2 mg33.3%
- GHRP-22 mg33.3%
What the label says is in a standard vial. It is not a dose, and not a lab test. The seller fixes the mix, so when you draw the amount you want of one ingredient, you get a set amount of every other one with it. No study has tested this mix in people or animals.
The studies we cite
- Study in people2006Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
A single shot of the long-acting version keeps growth hormone up for days. Here that is the problem, not the selling point. In healthy adults growth hormone ran two to ten times above its usual level for six days or more. IGF-1 stayed high for nine to eleven days. After repeat doses, IGF-1 was still above where it started 28 days later. Half a dose is still in the body a week on. This ingredient shares a vial with two that are gone in hours.
Single subcutaneous injections in healthy adults raised mean plasma growth hormone two to ten-fold for six days or more and IGF-1 1.5 to three-fold for nine to eleven days, with an estimated half-life of 5.8 to 8.1 days and IGF-1 above baseline for up to 28 days after multiple doses. A component lasting that long shares this vial with two that clear in hours.
- Study in people2004Sustained elevation of pulsatile growth hormone (GH) secretion and insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and IGFBP-5 concentrations during 30-day continuous subcutaneous infusion of GH-releasing peptide-2 in older men and women
One hunger-hormone type peptide plus GHRH is enough to show the effect. That is the point to take from this study. Healthy older adults given the pair through a 24 hour drip made more growth hormone than with either drug alone. Nobody has tested adding a second peptide that presses the same switch as the first. Nothing in this research says two is better than one. The vial holds two anyway.
A 24 hour infusion combining a ghrelin-receptor agonist with GHRH raised growth hormone secretion above either agent given alone in healthy older adults. One GHRP was enough to show the two-receptor effect; nothing in this literature supports adding a second agent at the same receptor.
- Study in people2005Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men
GHRP-2 makes healthy men eat more, and that matters here more than anywhere. Ipamorelin was picked from this drug family because it lifts growth hormone without dragging hunger along. Put GHRP-2 in the same vial and the hunger comes right back. The one thing the ipamorelin in this blend was chosen for is cancelled by the peptide next to it.
GHRP-2 increased food intake in healthy men. This is the profile ipamorelin was selected to avoid, and it returns to the vial the moment GHRP-2 is added alongside it.
- Study in people2014Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients
Ipamorelin has been through one real study in people, and it was about recovery after bowel surgery. 117 patients got either ipamorelin into a vein twice a day or a dummy drip, by chance. It was safe. The study measured how soon patients could handle a solid meal. That is the whole proper record for this peptide in people. It says nothing about the uses it is sold for here.
117 bowel resection patients randomised to intravenous ipamorelin or placebo twice daily. Safe, and the key efficacy endpoint of time to tolerating a solid meal was the measure it was tested against. This is the only randomised controlled trial of ipamorelin in people.
Where to buy CJC-1295 with ipamorelin and GHRP-2
No seller we track lists CJC-1295 with ipamorelin and GHRP-2 yet. We read sellers’ public product lists every week, and this section fills in as soon as one does. Every seller, graded
Common questions
Has CJC-1295 with ipamorelin and GHRP-2 been tested in people?
Yes. 117 people given it across 2 completed trials cited here, 0 of which found nothing. CJC-1295 with ipamorelin and GHRP-2 is three growth hormone boosters in one vial, often 2 mg each in a 6 mg vial.
What is the CJC-1295 with ipamorelin and GHRP-2 dosage?
No human dose established. Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose. 2 completed trials, 117 people given it
Is CJC-1295 with ipamorelin and GHRP-2 FDA-approved?
Not approved. None of the three parts is an approved medicine in the United States, and no regulator has reviewed any mix of them.
Are ipamorelin and GHRP-2 two different mechanisms?
No. Both press the same switch, the hunger hormone switch. Putting both in a vial is closer to a bigger dose of one than to a second way of working.
Why is that a problem?
Ipamorelin was picked from this family because it causes less of a rise in the stress hormone cortisol, the hormone prolactin, and hunger than the older peptides. GHRP-2 is one of the older peptides. Adding it back brings back the very effects ipamorelin exists to avoid.
What does one unit deliver?
Take a 6 mg vial with 2 mg of each, mixed with 2 mL of water. Each unit mark holds 10 micrograms of each. A 10 unit draw is 100 micrograms of each. That is 200 micrograms of hunger-switch peptide in total.
How often should this be injected?
No timing fits. If the vial holds the long-acting CJC-1295 with DAC, half of that one is gone only after 5.8 to 8.1 days. The other two are gone in hours. Daily dosing builds up one. Weekly dosing wastes two.
Has the three-way combination been tested?
No, in people or animals. The only pairing work for this kind of drug used one GHRP with GHRH, by drip, in a research unit.